Biohaven (BHVN) Total Non-Current Liabilities (2021 - 2026)

Biohaven (BHVN) reported Total Non-Current Liabilities of $332.3 million for Q1 2026, up 199.06% on a YoY basis from $111.1 million in Q1 2025, and down 15.82% sequentially from $394.8 million in Q4 2025.

Biohaven (BHVN) Total Non-Current Liabilities (2021 - 2026) Analysis & Trends

Biohaven (BHVN) has 6 years of Total Non-Current Liabilities data on file, last reported at $332.3 million in Q1 2026.

  • For the quarter ending Q1 2026, Total Non-Current Liabilities rose 199.06% year-over-year to $332.3 million; the trailing twelve-month figure through Mar 2026 stood at $332.3 million (up 199.06% YoY), and the FY2025 full-year result was $394.8 million, up 111.11% from the prior year.
  • Total Non-Current Liabilities slipped to $332.3 million in Q1 2026, from $394.8 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $394.8 million in Q4 2025 to a low of $28.4 million in Q3 2022.
  • A 5-year average of $161.6 million and a median of $143.8 million in 2023 frame the typical range for Total Non-Current Liabilities.
  • Peak annual rise in Total Non-Current Liabilities reached 218.14% in 2023, while the deepest fall reached 31.19% in 2023.
  • Tracing BHVN's Total Non-Current Liabilities over 5 years: stood at $120.6 million in 2022, then slumped by 31.19% to $83.0 million in 2023, then jumped by 125.33% to $187.0 million in 2024, then jumped by 111.11% to $394.8 million in 2025, then declined by 15.82% to $332.3 million in 2026.
  • Business Quant data shows BHVN's Total Non-Current Liabilities at $332.3 million in Q1 2026, $394.8 million in Q4 2025, and $158.0 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - 4.45 Mn
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - 110.28 Mn
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 1.98 Bn
4 NuCana 279.75 Bn 279.75 Bn - 949,738.67
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 5.87 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 7.32 Bn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 40.00 Mn
9 Revolution Medicines 37.78 Bn 37.78 Bn - 746.94 Mn
10 Biohaven 2.16 Bn 1.81 Bn - 332.35 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 332.35 Mn
Dec 31, 2025 394.79 Mn
Sep 30, 2025 158.01 Mn
Jun 30, 2025 158.76 Mn
Mar 31, 2025 111.13 Mn
Dec 31, 2024 187.01 Mn
Sep 30, 2024 189.93 Mn
Jun 30, 2024 194.58 Mn
Mar 31, 2024 113.67 Mn
Dec 31, 2023 82.99 Mn
Sep 30, 2023 90.46 Mn
Jun 30, 2023 116.96 Mn
Mar 31, 2023 143.77 Mn
Dec 31, 2022 120.60 Mn
Sep 30, 2022 28.44 Mn
Dec 31, 2021 44.73 Mn